With the reduction of COVID-19 testing and companies starting to recover testing revenues, there has been a tendency to say: we are back to 2019 levels. In an upcoming webinar this Wednesday, EYE on IVD we will dispute this, we will make the case that the in vitro diagnostic market for infectious diseases is not merely “back to the pre-COVID-19 era.” While there has been a reduction in testing for COVID-19, particularly asymptomatic testing that characterized a few years ago, there are longer-term changes that make this new era different because of what the healthcare system experienced during the pandemic.
We will not be the same, especially not in infectious disease IVD. It is not 2019, we will state in one of our many slides in the upcoming INFECTIOUS IVD TRENDS AND OPPORTUNITY WEBINAR on Wednesday, November 6th, 2024. There are fundamental changes in installed bases, and recognition of the value of life-saving tests that will affect the market in the next ten years and beyond. On top of that, COVID-19 has not disappeared.
60 attendees so far have signed up for the webinar .
SIGN UP TODAY: https://us06web.zoom.us/webinar/register/WN_cSEbd8ITSGavClaSRdMDXw
There are four reasons given for this situation:
- First, markets for IVD products did not just settle back to 2019 levels; there is currently a 23% larger infectious disease IVD testing market than existed in 2019 (37 billion vs. 30 billion) according to Eye On IVDs Infectious Disease Market Report
- Secondly, the installed base of equipment has grown. Abbott for instance, quadrupled installations of its IDNOW system from estimated 19,000 to 75,000, per media reports. This is only one instance – gains have been seen in Quidel Ortho systems, BD systems, and large molecular analyzers have installed bases unheard of in 2019. This testing capability is being put to bear in other areas.
- The presence and acceptance of respiratory panels achieving payor confidence for outcomes improvement, particularly in panels of a few tests. Also the increase in product launches.
- Finally, COVID -19 is still a threat. It is not MERS or SARS 2003, it remains on the menu, it remains a threat particularly in sick patients and for differential diagnosis.
To the last point, Carlson will note the St. Louis Veterans Affairs Study that determined that COVID-19 . was 35% deadlier than the flu in hospital patients, thus justifying its separate identification.
Eye On IVD’s webinar will be held live on Wednesday, November 6th, 2024.
